Pulse Biosciences (Nasdaq:PLSE) announced a new strategic alignment to focus on its nPulse cardiac catheter ablation system.
MedPage Today on MSN
GLP-1 Drugs Show Growing Promise for Afib Control
Good outcomes relative to bariatric surgery after catheter ablation in observational data ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and ...
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation ...
LUMA Vision, a leader in cardiac 4D imaging and navigation, today announces the expansion of its clinical program with the ...
Luma Vision announced today that it expanded its clinical program following the latest submission of its Verafeye platform to ...
In an era where software moats erode overnight, we are drawn to businesses fortified by hardware, patents, approvals and 20 ...
Heart rhythm disorders like AFib can raise stroke and heart failure risk. Early diagnosis and catheter ablation can restore ...
Leerink Global Healthcare Conference 2026 March 11, 2026 9:20 AM EDTCompany ParticipantsThierry Pieton - Executive VP ...
Zacks Investment Research on MSN
Reasons to Add AngioDynamics Stock to Your Portfolio for Now
AngioDynamics ANGO has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment markets. The optimism, led by a solid first-quarter fiscal 2026 performance, ...
Detailed price information for Profound Medical Corp (PRN-T) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results